You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華潤醫藥(03320.HK)上半年純利降5.40%至24.38億港元
格隆匯 08-25 12:21

格隆匯8月25日丨華潤醫藥(03320.HK)公佈中期業績,截至2021年6月30日止6個月,公司收益為1144.88億港元,同比增長28.08%;毛利為174.65億港元,同比增長17.48%;公司擁有人應占期內溢利為24.38億港元,同比下降5.40%;基本及攤薄每股盈利為人民幣0.39港元。

公吿稱,純利下降主要由於分銷板塊的利潤貢獻同比下降。

2021年上半年製藥、醫藥分銷、藥品零售三個主要業務分部的收益佔比分別為14.9%、81.9%以及3.1%。

製藥業務,報吿期間內,集團製藥業務實現分部收益187.96億港元,較2020年上半年增長35.2%,按照人民幣口徑同比增長24.5%,主要受疫情緩解影響及數字化轉型戰略成效凸顯,核心業務自我診療板塊及處方藥板塊收入增幅顯著。

醫藥分銷業務,報吿期間內,集團醫藥分銷業務實現分部收益963.04億港元,較2020年上半年增長27.2%,按照人民幣口徑增長17.1%。2021年上半年分銷業務毛利率為6.2%,較上年同期下降1.7個百分點,主要由於疫情緩解,毛利率水平較高的防疫物資出口業務收入減少。

醫藥零售業務,報吿期間內,集團醫藥零售業務錄得收益35.94億港元,較2020年上半年同比增加20.1%(按照人民幣口徑同比增加10.6%),主要因為高值藥品直送業務("DTP")業務收入增速較快,集團的DTP業務2021年上半年實現收益約人民幣20.96億元,同比增長約21.3%。零售業務毛利率為9.0%,較上年同期比下降2.1個百分點,毛利率水平的下降主要因為毛利率較低的DTP業務收入比重增加。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account